Recent Updates — CRDF
Dr. Roger Sidhu separated from Cardiff Oncology, Inc., and Dr. Leila Alland was appointed interim Chief Medical Officer effective October 23, 2026, under a consulting agreement paying $35,000 monthly until April 22, 2027. The company also filed a Certificate of Amendment to increase its authorized common stock to 300,000,000 shares. Cardiff Oncology is a clinical-stage biotechnology company targeting RAS-mutated cancers via PLK1 inhibition.
Cardiff Oncology stockholders approved an amendment to the Certificate of Incorporation at a Special Meeting on October 22, 2026. The vote increased the total authorized capital stock from 170 million to 320 million shares and raised the number of authorized common shares from 150 million to 300 million. The proposal received approximately 37.7 million votes in favor against roughly 10.1 million opposed. Cardiff Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer.
Cardiff Oncology and Nerviano Medical Sciences entered a Confidential Settlement Agreement to resolve patent inventorship and license performance litigation, dismissing the case with prejudice without monetary payment. Concurrently, they executed an Amendment to their 2017 Exclusive License Agreement for onvansertib, establishing an updated exclusivity framework preventing Nerviano from developing competing products. The amendment introduces additional license fees based on annual net sales of Company-patented products, revised post-termination royalty tiers, and development milestones tied to the upcoming Phase 3 program in first-line RAS-mutated metastatic colorectal cancer. Nerviano gains a board observer seat and a Scientific Advisory Board position, while termination-for-cause provisions now require judicial or arbitral determination of material breach. Cardiff Oncology is a clinical-stage biotechnology company advancing innovative cancer treatments focused on PLK1 inhibition.
Cardiff Oncology reported second quarter 2026 financial results and provided a business update. The company completed a $10 million registered direct offering of common stock and warrants to support working capital. As of June 30, 2026, Cardiff held approximately $34.5 million in cash, cash equivalents, and short-term investments. Net cash used in operating activities for the six months ended June 30, 2026 was approximately $24.1 million. The company plans to initiate a Phase 3 registrational trial of onvansertib in first-line RAS-mutated metastatic colorectal cancer in Q1 2027, subject to securing additional financing. Cardiff Oncology is a clinical-stage biotechnology company developing novel cancer therapies leveraging PLK1 inhibition.
Cardiff Oncology, Inc. entered into a securities purchase agreement on July 14, 2026, to sell 8,571,429 shares of common stock and accompanying warrants to institutional investors at $1.05 per share and warrant. Additionally, certain officers and directors purchased 721,649 shares at $1.455 per share. The offering, which closed on July 16, 2026, raised approximately $10.05 million in gross proceeds for working capital and general corporate purposes. Cardiff Oncology is a clinical-stage biotechnology company developing cancer therapies through PLK1 inhibition.